WO2002094173A3 - Tamper resistant oral dosage form - Google Patents

Tamper resistant oral dosage form Download PDF

Info

Publication number
WO2002094173A3
WO2002094173A3 PCT/US2002/016269 US0216269W WO02094173A3 WO 2002094173 A3 WO2002094173 A3 WO 2002094173A3 US 0216269 W US0216269 W US 0216269W WO 02094173 A3 WO02094173 A3 WO 02094173A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
oral dosage
tamper resistant
resistant oral
cleavage
Prior art date
Application number
PCT/US2002/016269
Other languages
French (fr)
Other versions
WO2002094173A2 (en
Inventor
Curtis Wright Iv
Original Assignee
Purdue Pharma Lp
Curtis Wright Iv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp, Curtis Wright Iv filed Critical Purdue Pharma Lp
Priority to EP02753331A priority Critical patent/EP1395224A4/en
Priority to US10/478,879 priority patent/US20040156844A1/en
Priority to AU2002313628A priority patent/AU2002313628A1/en
Publication of WO2002094173A2 publication Critical patent/WO2002094173A2/en
Publication of WO2002094173A3 publication Critical patent/WO2002094173A3/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells

Abstract

The present invention provides an oral dosage form including a medicament and an insoluble component adhered to or encapsulates the medicament that is susceptible to cleavage by colonic bacteria and resistant to cleavage by intestinal saccharidases.
PCT/US2002/016269 2001-05-22 2002-05-22 Tamper resistant oral dosage form WO2002094173A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02753331A EP1395224A4 (en) 2001-05-22 2002-05-22 Tamper resistant oral dosage form
US10/478,879 US20040156844A1 (en) 2002-05-22 2002-05-22 Tamper resistant oral dosage form
AU2002313628A AU2002313628A1 (en) 2001-05-22 2002-05-22 Tamper resistant oral dosage form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29260301P 2001-05-22 2001-05-22
US60/292,603 2001-05-22

Publications (2)

Publication Number Publication Date
WO2002094173A2 WO2002094173A2 (en) 2002-11-28
WO2002094173A3 true WO2002094173A3 (en) 2003-02-20

Family

ID=23125385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016269 WO2002094173A2 (en) 2001-05-22 2002-05-22 Tamper resistant oral dosage form

Country Status (3)

Country Link
EP (1) EP1395224A4 (en)
AU (1) AU2002313628A1 (en)
WO (1) WO2002094173A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
JP2006515622A (en) * 2003-01-13 2006-06-01 ニュー リバー ファーマシューティカルズ インコーポレイテッド Carbohydrate conjugates to prevent the abuse of controlled substances
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001166A1 (en) * 1993-06-30 1995-01-12 Fujisawa Pharmaceutical Co., Ltd. Encapsulated medicine
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001166A1 (en) * 1993-06-30 1995-01-12 Fujisawa Pharmaceutical Co., Ltd. Encapsulated medicine
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1395224A4 *

Also Published As

Publication number Publication date
EP1395224A4 (en) 2005-10-26
AU2002313628A1 (en) 2002-12-03
EP1395224A2 (en) 2004-03-10
WO2002094173A2 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
GB9925962D0 (en) Organic compounds
MXPA03010007A (en) Pharmaceutical uses of bisphosphonates.
WO2004075736A3 (en) Aneurysm neck obstruction device
ZA200402976B (en) Electronic pull tab gaming system.
WO2000064930A3 (en) Tribonectins
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
AU2002352344A1 (en) Medicament delivery assembly
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
MXPA03010549A (en) Oxcarbazepine dosage forms.
BR0013110A (en) Oral form of administration containing probiotic microorganisms
ZA200305803B (en) Prevention of diabetes by administration of GnRH antagonists.
AU2002352410A1 (en) Improved oral medicine dispenser
BR0314129A (en) Modified release formulations of oxcarbazepine and derivatives thereof
WO2002094173A3 (en) Tamper resistant oral dosage form
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
AU2002317259A1 (en) Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
HRP20040186B1 (en) Use of lhrh-antagonists for the improvement of t-cell mediated immunity
AUPS286302A0 (en) Medication inhaler
AP2001002369A0 (en) Pharmaceutical complex.
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
GB0220740D0 (en) Administration of a system
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
AU2002100617A4 (en) S.A.M. (Self-administering medicine) pacifier
AU2003232698A1 (en) Use of a n,n'-dibenzyl-thiourea as medicine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10478879

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002753331

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002753331

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP